Neuropsychopharmacology Reports
August 27, 2026
Futaba Umemura, Hiroko Kotajima‐Murakami, Justin C. Strickland et al.
INTRODUCTION: Interest in therapeutic applications of psychedelics has recently resurged. Mystical-type and challenging experiences that are elicited by psychedelics are commonly assessed using the 30-item Mystical Experience Questionnaire (MEQ-30) and the 26-item Challenging Experience Questionnaire (CEQ), respectively. The brief 4-item MEQ (MEQ-4) and 7-item CEQ (CEQ-7) may reduce respondent...
Neuropsychopharmacology Reports
November 23, 2025
Hideaki Kato, Yoshimi Ichimaru, Masaaki Kurihara et al.
1 citation
AIM: The regulation of new psychoactive and dangerous abused substances is very important for the prevention of drug abuse. A simple and effective evaluation method using laboratory animals is needed to regulate designated drugs with high accuracy and speed. METHODS: receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI), which have a similar mechanism of action to...
Neuropsychopharmacology Reports
July 20, 2025
Zofia Kachlik, Wiesław Jerzy Cubała, Michał Walaszek et al.
3 citations
OBJECTIVES: Ketamine is a prototypical rapid-acting antidepressant for treatment-resistant bipolar depression (TRBD), yet many patients do not achieve a meaningful response. This study explored features of ketamine nonresponse in TRBD. METHODS: In a post hoc analysis of a naturalistic study, 35 TRBD patients received a four-week ketamine regimen (intravenous 0.5 mg/kg or oral 2.0/2.5 mg/kg)....
Neuropsychopharmacology Reports
March 1, 2025
Naoya Nishitani, Yuki Sasaki, Katsuyuki Kaneda
3,4-methylenedioxymethamphetamine (MDMA), a commonly abused recreational drug, induces prosocial effects such as increased sociability and empathy. The nucleus accumbens (NAc) has been suggested to play a crucial role in these MDMA-mediated prosocial effects. However, the relationship between social behavior and NAc neural activity, and the effects of MDMA on this relationship, remain unknown....
Neuropsychopharmacology Reports
December 1, 2024
Ghada Shahrour, Kainat Sohail, Safa Elrais et al.
21 citations
Post-traumatic stress disorder (PTSD) is a mental health disorder resulting from exposure to traumatic events, manifesting in various debilitating symptoms. Despite available treatments, many individuals experience inadequate response or significant side effects. Previous reviews suggest promising outcomes with MDMA-assisted psychotherapy (MDMA-AT), but limitations prompt the need for a...
Neuropsychopharmacology Reports
November 8, 2024
Hideaki Tani, Kengo Yonezawa, Keisuke Kusudo et al.
1 citation
Abstract Introduction The therapeutic potential of psychedelics for various mental disorders has gained significant interest. Previous studies have highlighted that psychedelics induce psychoactive effects, including challenging aspects of experiences. These experiences are assessed using the Challenging Experience Questionnaire (CEQ), yet its Japanese version has been unavailable. This study...
Neuropsychopharmacology Reports
March 13, 2024
Kengo Yonezawa, Hideaki Tani, Shinichiro Nakajima et al.
5 citations
Abstract Introduction Psychedelics have garnered increased attention as potential therapeutic options for various mental illnesses. Previous studies reported that psychedelics cause psychoactive effects through mystical experiences induced by these substances, including an altered state of consciousness. While this phenomenon is commonly assessed by the Mystical Experiences Questionnaire...
Neuropsychopharmacology Reports
March 13, 2024
Keisuke Kusudo, Hideaki Tani, Kengo Yonezawa et al.
2 citations
Abstract Aim Psychedelics have recently gained attention as potential therapeutic agents for various psychiatric disorders. Previous research has highlighted that a diminished sense of self, commonly termed “ego‐dissolution” is a pivotal feature of the psychedelic‐induced state. While the Ego‐Dissolution Inventory (EDI) is a widely acknowledged instrument for measuring this phenomenon, no...
Neuropsychopharmacology Reports
March 1, 2023
Yuji Masataka, Takeshi Sugiyama, Yoshiyuki Akahoshi et al.
To determine the risk factors for cannabis use disorders and cannabis psychosis in Japan based on a 2021 online survey among Japanese users of social network services. The 3142 respondents who had used cannabis within the preceding year were categorized into two groups based on the development of cannabis use disorder and/or cannabis psychosis. Analyses were performed to determine these...
Neuropsychopharmacology Reports
February 21, 2021
Tomoyuki Nakamura, Masaru Tomita, N. Horikawa et al.
29 citations
Approximately one‐third of patients with major depressive disorder develop treatment‐resistant depression. One‐third of patients with treatment‐resistant depression demonstrate resistance to ketamine, which is a novel antidepressant effective for this disorder. The objective of this study was to examine the utility of resting‐state functional magnetic resonance imaging for the prediction of...
Neuropsychopharmacology Reports
February 6, 2021
Yoko Hagino, F. Scott Hall, George R. Uhl et al.
3 citations
Abstract Aims 5‐Methoxy‐ N , N ‐diisopropyltryptamine (5‐MeO‐DIPT) is a synthetic orally active hallucinogenic tryptamine analogue. The present study examined whether the effects of 5‐MeO‐DIPT involve the serotonin transporter (SERT) and serotonin 5‐hydroxytryptamine‐1A (5‐HT 1A ) receptor in the striatum and prefrontal cortex (PFC). Methods We investigated the effects of 5‐MeO‐DIPT on...